AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia

Related Experiment Videos

R Boccia, J Zighelboim, R E Champlin

Medical and Pediatric Oncology

|January 1, 1984

Abstract:

27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA. Three achieved a complete remission, and two a partial remission. Median survival for all patients was 12 weeks and was 16 weeks for responders.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Axisymmetric Eigenmodes Excited by Alpha Particle Energy Gradients in JET D-T Plasmas.

Physical review letters·2026

Blood glucose control and metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes.

Journal of endocrinological investigation·2024

Antineoplastic drug occupational exposure: a new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker.

Toxicology letters·2019

Association of clinicopathological features of melanoma with total naevus count and a history of dysplastic naevi: a cross-sectional retrospective study within an academic centre.

Clinical and experimental dermatology·2018

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients.

Bone marrow transplantation·2016

PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.

Leukemia·2016

See all related articles